uniQure's (QURE) Buy Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright reaffirmed a Buy on uniQure with a $70 price target, implying roughly a 289% upside from the prior close.
• Analyst coverage is mixed — 9 Buys, 7 Holds and 1 Sell with a consensus "Hold" and $41.33 target; the stock trades around $18 (market cap ~$1.12B) and the company recently beat quarterly EPS and revenue but remains highly unprofitable.
• Regulatory and legal risk around AMT-130 (FDA trial‑design dispute and related securities class‑action notices) plus recent insider selling are key downside risks ahead of binary clinical/regulatory catalysts.

uniQure (NASDAQ:QURE - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $70.00 target price on the biotechnology company's stock. HC Wainwright's price target would suggest a potential upside of 289.11% from the company's previous close.

Other research analysts also recently issued research reports about the company. Leerink Partners restated an "outperform" rating and issued a $35.00 price objective on shares of uniQure in a research note on Monday, March 2nd. TD Cowen reissued a "buy" rating on shares of uniQure in a research report on Tuesday, March 3rd. Chardan Capital upped their price target on uniQure from $16.00 to $31.00 and gave the company a "buy" rating in a research report on Monday. The Goldman Sachs Group lowered their target price on shares of uniQure from $37.00 to $9.00 and set a "neutral" rating on the stock in a report on Tuesday, March 3rd. Finally, Royal Bank Of Canada upgraded uniQure from a "sector perform" rating to an "outperform" rating and lifted their price target for the company from $11.00 to $35.00 in a research report on Monday. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $41.33.

uniQure Price Performance

Shares of QURE opened at $17.99 on Tuesday. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -5.21 and a beta of 0.73. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The business has a 50-day moving average of $21.90 and a 200-day moving average of $29.64.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. As a group, equities research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Insider Activity at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of uniQure stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the transaction, the director directly owned 20,439 shares of the company's stock, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew C. Kapusta sold 14,581 shares of the company's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $132,103.86. Following the sale, the chief executive officer owned 660,658 shares of the company's stock, valued at approximately $5,985,561.48. The trade was a 2.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 81,399 shares of company stock worth $1,527,645 in the last quarter. 4.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Private Trust Co. NA purchased a new position in shares of uniQure during the third quarter valued at approximately $28,000. Jones Financial Companies Lllp lifted its stake in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company's stock worth $33,000 after buying an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company's stock valued at $243,000 after acquiring an additional 533 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company's stock valued at $267,000 after purchasing an additional 627 shares in the last quarter. Finally, Ensign Peak Advisors Inc raised its position in uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company's stock worth $87,000 after buying an additional 650 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Multiple analyst upgrades and higher price targets — Wells Fargo raised QURE to "overweight" with a $60 target, Royal Bank of Canada upgraded to "outperform" with a $35 target, Chardan raised its target to $31 and H.C. Wainwright reaffirmed a Buy with a $70 target; these calls lift upside expectations and likely drove buying interest. uniQure: Regulatory Shift and AMT-130 Outlook Drive Reaffirmed Buy Rating and $70 Target
• Positive Sentiment: Sector/regulatory optimism after FDA leadership change — reports that FDA biologics chief Vinay Prasad will leave in April sparked a broader gene-therapy rally and has been cited as a catalyst lifting uniQure and peers, easing investor concerns about near-term regulatory friction. uniQure (QURE) Stock Soars 36% as FDA’s Vinay Prasad Plans April Exit
• Neutral Sentiment: Mixed analyst consensus — some aggregator reports show a consensus "Hold" from brokerages, indicating not all shops are turning uniformly bullish; this tempers the optimism and suggests differing views on AMT-130's probability of success. uniQure N.V. NASDAQ: QURE Receives Consensus Recommendation of "Hold" from Brokerages
• Neutral Sentiment: Analyst attention ahead of binary catalysts — coverage pieces highlight uniQure as a biotech with asymmetric upside around upcoming AMT-130 readouts/regulatory milestones; increased attention can boost liquidity but outcomes remain binary. uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
• Negative Sentiment: Wave of securities class-action notices — several law firms (Hagens Berman, Rosen, Faruqi & Faruqi, Levi & Korsinsky, Portnoy) have filed or announced investigations related to AMT-130 disclosures and a specific class period; potential litigation increases legal risk, distraction and possible financial exposure. QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design – Hagens Berman
• Negative Sentiment: Ongoing FDA/AMT-130 dispute and trial-design uncertainty — coverage describes growing confusion and regulatory pushback over AMT-130 trial design changes; that uncertainty could delay approvals or force costly additional studies, weighing on longer-term fundamentals. Confusion grows amid uniQure and FDA’s AMT-130 row

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.